JP6321658B2 - アミノ酸誘導体 - Google Patents
アミノ酸誘導体 Download PDFInfo
- Publication number
- JP6321658B2 JP6321658B2 JP2015532458A JP2015532458A JP6321658B2 JP 6321658 B2 JP6321658 B2 JP 6321658B2 JP 2015532458 A JP2015532458 A JP 2015532458A JP 2015532458 A JP2015532458 A JP 2015532458A JP 6321658 B2 JP6321658 B2 JP 6321658B2
- Authority
- JP
- Japan
- Prior art keywords
- pyrrolysine
- formula
- amino acid
- antibody
- moiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- JDKQTIKEGOOXTJ-UHFFFAOYSA-N C=CCCC(Cl)=O Chemical compound C=CCCC(Cl)=O JDKQTIKEGOOXTJ-UHFFFAOYSA-N 0.000 description 1
- DVFGVGYKHMQZJC-UHFFFAOYSA-N C=CCCC(N)=O Chemical compound C=CCCC(N)=O DVFGVGYKHMQZJC-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/49—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/56—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having carbon atoms of carboxamide groups bound to carbon atoms of carboxyl groups, e.g. oxamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
- C07C235/74—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C247/00—Compounds containing azido groups
- C07C247/02—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
- C07C247/04—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01025—1,4-Lactonase (3.1.1.25)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y601/00—Ligases forming carbon-oxygen bonds (6.1)
- C12Y601/01—Ligases forming aminoacyl-tRNA and related compounds (6.1.1)
Description
配列番号1:PylRSメタノサルシナ・マゼイ(Methanosarcina mazei)野生型ヌクレオチド配列
配列番号2:PylRSメタノサルシナ・マゼイ(Methanosarcina mazei)野生型アミノ酸配列
配列番号3:PylRSメタノサルシナ・マゼイ(Methanosarcina mazei)、Y384F突然変異ヌクレオチド配列
配列番号4:PylRSメタノサルシナ・マゼイ(Methanosarcina mazei)、Y384F突然変異アミノ酸配列
配列番号5:tRNApylメタノサルシナ・マゼイ(Methanosarcina mazei)
配列番号6:U6 snRNAプロモーター
配列番号7:U6−tRNApylコンストラクト
配列番号8:GFPヌクレオチド配列
配列番号9:GFPアミノ酸配列
配列番号10:GFPY40ヌクレオチド配列
配列番号11:GFPY40アミノ酸配列
配列番号12:抗Her2(4D5)γヌクレオチド配列
配列番号13:抗Her2(4D5)γアミノ酸配列
配列番号14:抗Her2(4D5)γ_K274アンバーヌクレオチド配列
配列番号15:抗Her2(4D5)γ_K274アンバーアミノ酸配列
配列番号16:抗Her2(4D5)κヌクレオチド配列
配列番号17:抗Her2(4D5)κアミノ酸配列
定義
用語「アミド」は−C(=O)−NH−結合を指す。
Z=結合、CH2、CH−NH2、CH−OH、NH、O、S又はCH−NH2;
bは0又は整数1〜7であり;及び
FG=アジド、アルケン、アルキン、ケトン、エステル、アリール又はシクロアルキン]
の構造を有する。
(2S)−2−アミノ−6−{[(2−アジドエトキシ)カルボニル]アミノ}ヘキサン酸
Z=CH2、CH−NH2、CH−OH、NH、O又はS;
FG=アジド、アルケン、アルキン、ケトン、エステル、アリール又はシクロアルキン;及び
b=整数1〜4]
の構造を有する。
(2S)−2−アミノ−6−{[(2−アジドエチル)カルバモイル]オキシ}ヘキサン酸
本明細書に開示されるピロリシン類似体は組換えタンパク質に組み込まれ得る。詳細には、アンバーサプレッションを用いて組換えタンパク質への類似体の部位特異的組込みを達成することができ、ここでは組換えタンパク質をコードするヌクレオチド配列中のピロリシン類似体を挿入しようとする部位にナンセンス(アンバー)コドンが挿入される。この突然変異ヌクレオチド配列が、PylRS及びtRNApylをコードする1つ以上のプラスミドと共に、無細胞発現系の細胞に挿入される。
組み込まれた本発明のピロリシン類似体を有するタンパク質は、機能化タンパク質コンジュゲートの調製に用いられ得る。組み込まれた非天然アミノ酸を有するタンパク質とコンジュゲートされ得る分子には、(i)他のタンパク質、例えば抗体、特にモノクローナル抗体;(ii)ポリマー、例えばPEG基又はその系の半減期を延長させ得る他の基;(iv)細胞傷害剤、例えばアウリスタチンF;及び(v)薬物部分、例えばドキソルビシン及び放射性同位体を含む部分が含まれる。さらにこのような修飾タンパク質を、薬物又はそうした強力な化合物の標的化デリバリー用のヌクレオチドにコンジュゲートしてもよい。
標的タンパク質はPEG部分にコンジュゲートされ得る。PEG部分は抗体薬物コンジュゲートに組み込まれ得る。PEG部分は、典型的には0.5kDa〜40kDa、例えば5kDa〜40kDaの範囲の分子量を有し得る。より好ましくは、PEG部分は約20kDaの分子量を有し得る。加えて、PEG部分は100〜2000Daの範囲の分子量を有し得る。PEG部分は直鎖状又は分枝状又はマルチアーム型であってもよい。
本発明に係るピロリシン類似体は、抗体当たりの薬物(又は他のコンジュゲートされる分子)の数及び抗体におけるそれらの薬物の位置が明確に制御された均一な性質の抗体薬物コンジュゲート(所与の薬物、典型的には細胞傷害性薬物、或いはタンパク質又はPEG基に合成リンカーによって共有結合した組換え抗体)の作製に特に有用であり、従って組み込まれた非天然アミノ酸を含むモノクローナル抗体が得られ、これは直交化学により薬物部分(又は他のコンジュゲートされる分子)を有するリンカーと部位特異的にコンジュゲートされる。
1.本発明の安定細胞株に、完全長抗体をコードするDNA配列を有する1つ以上のプラスミドを導入するステップであって、それにより配列内の特定の位置に終止コドンが導入されるステップ
2.ピロリシン類似体(nnAA)が所望の1つ又は複数の位置に導入された修飾抗体を精製するステップ
3.抗体に導入されたnnAAに相補的な官能基を含むように修飾された細胞毒−リンカー誘導体を、相補的な反応基を含む修飾抗体と直交化学によって反応させるステップ
4.得られたADCを精製するステップ
細胞毒薬物部分などの本発明の薬物部分としては、小分子、天然産物、合成的に誘導された薬物、免疫毒素などのタンパク質、及び放射性核種が挙げられる。
本明細書に記載されるピロリシン類似体は、場合により塩の形態で用いられ得る。任意のかかる塩が本発明の態様を形成する。カルボン酸の塩には、第1族及び第2族金属と形成される塩、特にナトリウム塩及びカリウム塩などの可溶性塩が含まれ得る。アミンの塩には、HCl、HBr又は酢酸などの弱酸及び強酸と形成される塩が含まれ得る。
(2S)−2−アミノ−6−(ペンタ−4−エナミド)ヘキサン酸(式V.5)の調製
インビトロ細胞ベースアッセイを開発して、pylRS/tRNA対と本発明のピロリシン類似体(nnAA)の適合性及び標的タンパク質へのnnAAの組込み効率を評価した。このために、pylRS(3H7)を安定に発現するHEK293細胞に、標準的なトランスフェクションプロトコルを用いてtRNApylの発現用プラスミド及びGFPY40をコードするレポーターコンストラクト(アミノ酸残基40番(ここでは1番が開始因子メチオニンである)にチロシンの代わりにアンバーコドンを含む)を一過性にトランスフェクトした。トランスフェクト細胞を2mMのnnAAと共に2〜3日間インキュベートした。GFP産生を顕微鏡下目視で観察することによって定性的に分析した。GFP蛍光はAccuriフローサイトメーターを使用したフローサイトメトリーにより定量化し、蛍光細胞の幾何平均を決定した。
2つの非天然アミノ酸(各重鎖に1つずつ)を含む完全長抗Her2抗体(4D5−2AZ ab)を哺乳類細胞で発現させた。nnAA(アジド部分を含む)を選択した部位に組み込み、プロテインA樹脂(GE Healthcare)か或いはIgSelect(GE Healthcare、17096901)を使用するアフィニティークロマトグラフィーにより精製した。次に精製した材料を濃縮し、コンジュゲーション反応に供した。
200uL PCRチューブにリン酸緩衝液(5uL、500mM、pH=7.4)を入れた。4D5−2AzAb−HC274−(2S)−2−アミノ−6−{[(2−アジドエチル)カルバモイル]オキシ}ヘキサン酸(式VI.1)の溶液(10uL、0.55mg/mL)を添加し、続いて20KPEGシクロオクチンの溶液(3.3、60mg/mL)を添加した。この溶液をボルテクサーで激しく混合した。混合物を一晩静置しておいた。混合物を200uLに希釈し、プロテインA磁気ビーズに加えた。混合物をボルテックスし、回転させてビーズを90分間混合した。ビーズを固定化し、流れ抜ける物質は廃棄した。ビーズをPBS(2×)で洗浄し、次に還元ゲル緩衝液に懸濁した。ボルテックスし、次に95Cに3分間加熱した。懸濁液をSDS−PAGEゲルに直接ロードした。SDS−PAGEゲルのクーマシー(Commassie)染色は、重鎖の選択的なペグ化を示した(図1、レーン3)。
200uL PCRチューブにリン酸緩衝液(65uL、50mM、pH=7.4)を入れた。4D5−2AzAb−HC274−(2S)−2−アミノ−6−{[(2−アジドエチル)カルバモイル]オキシ}ヘキサン酸の溶液(30uL、0.55mg/mL)を添加し、続いて溶液DMCO−Fluor 488シクロオクチン(5.4、DMSO中5mM、クリックケミストリーツール)を添加した。この溶液をボルテクサーで激しく混合した。混合物を24時間静置しておいた。混合物をHICクロマトグラフィー(1M硫酸ナトリウムからリン酸緩衝液への勾配を含む東ソーTSKgel Butyl NPR)により分析すると、コンジュゲーションが起こり、1つ又は2つの部位でコンジュゲーションが起こった混合物(概してDAR1種及びDAR2種と称される;ここでDARは薬物対抗体比として定義される)が得られたことが示された(図2)。
配列番号1
PylRSメタノサルシナ・マゼイ(Methanosarcina mazei)野生型ヌクレオチド配列
PylRS、メタノサルシナ・マゼイ(Methanosarcina mazei)野生型アミノ酸配列
PylRSメタノサルシナ・マゼイ(Methanosarcina mazei)Y384F突然変異ヌクレオチド配列
PylRSメタノサルシナ・マゼイ(Methanosarcina mazei)Y384F突然変異アミノ酸配列
tRNApylメタノサルシナ・マゼイ(Methanosarcina mazei)Go1
U6 snRNAプロモーター
U6−tRNApylコンストラクト
GFPヌクレオチド配列
GFPアミノ酸配列
GFPY40ヌクレオチド配列
GFPY40アミノ酸配列
抗Her2(4D5)γヌクレオチド配列
抗Her2(4D5)γアミノ酸配列
抗Her2(4D5)γ_K274アンバーヌクレオチド配列
抗Her2(4D5)γ_K274アンバーアミノ酸配列
抗Her2(4D5)κヌクレオチド配列
抗Her2(4D5)κアミノ酸配列
Fekner,T.,Li,X.,& Chan,M.K.(2010).Pyrrolysine Analogs for Translational Incorporation into Proteins.European Jouranal of Organic Chemistry,4171−4179
Kavran,J.M.,Gundllapalli,S.,O’ Donoghue,P.,Englert,M.,Soll,D.,& Steltz,T.A.(2007).Structure of pyrrolysyl−tRNA synthetase,an archaeal enzyme for genetic code innovation.Proceedings National Academy of Sciences,104(27),11268−11273
Kobayashi,T.,Yanagisawa,T.,Sakamoto,K.,& Yokoyama,S.(2009).Recognition of Non−a−amino Substrates by Pyrrolysyl−tRNA Synthetase.J.Mol.Biol.(1352−1360),385
Liu,Chang C,and Peter G Schultz.“Adding New Chemistries to the Genetic Code.”Annual Review of Biochemistry,2010:413−444
Chan,Michael K,Tomasz Fekner,Xin Li,Marianne Lee,and Jennifer J Ottesen.International Patent WO2011/044255A1.2011
Nguyen,D.P.,Lusic,H.,Neumann,H.K.,Deiters,A.,& Chin,J.W.(2009).Genetic Encoding and Labeling of Aliphatic Azides and Alkynes in Recombinant Proteins via a Pyrrolysyl−tRNA Synthetase/tRNAcua Pair and Click Chemistry.Journal of the American Chemical Society,8720−8721
Yanagisawa,T.,Ishii,R.,Fukunaga,R.,Kobayashi,T.,Sakamoto,K.,& Yokoyama,S.(2008).Crystallographic Studies on Multiple Conformational States of Active−site loops in Pyrrolysyl−tRNA synthetase.J.Mol.Biol.,378,634−652
Yanagisawa,T.,Ishii,R.,Fukunaga,R.,Kobayashi,T.,Sakamoto,K.,& Yokoyama,S.(2008).Multistep Engineering of Pyrrolysyl−tRNA Synthetase to Genetically Encode Ne−(o−Azidobenzyloxycarbonyl)lysine for Site Specific Protein Modification.Chemistry and Biology,15,1187−1197
Yanagisawa,T.,Sumida,T.,Ishii,R.,& Yokoyama,S.(2013).A novel crystal fom of pyrrolysyl−tRNA synthetase reveals the pre− and post−aminoacyl−tRNA synthesis conformational states of the adenylate and aminoacyl moieties and an asparagine residue in the catalytic site.Acta Crystallographica Section D,D69,5−15
本発明の実施形態として、例えば以下を挙げることができる。
(1) 式VI:
[式中
Z=CH2、CH−NH2、CH−OH、NH、O、S;
FG=アジド、アルケン、アルキン、ケトン、エステル、アリール又はシクロアルキン;及び
b=整数1〜4である]
で表されるピロリシン類似体。
(2) ZがNHである、(1)に記載の式VIのピロリシン類似体。
(3) bが1又は2である、(1)又は(2)に記載の式VIのピロリシン類似体。
(4) FGが、−N3、−CH=CH2、−C≡CH、−COCH3、COOCH3、ハロゲンによって置換されたフェニル、又はシクロオクチンを表す、(1)〜(3)のいずれかに記載の式VIのピロリシン類似体。
(5)
から選択される、(1)に記載のピロリシン類似体。
(6)
から選択されるピロリシン類似体。
(7) (1)〜(6)のいずれかに記載の1つ以上のピロリシン類似体を非天然アミノ酸として含む突然変異タンパク質。
(8) (1)〜(6)のいずれかに記載の1つのピロリシン類似体を非天然アミノ酸として含む、(7)に記載の突然変異タンパク質。
(9) 各重鎖及び/又は軽鎖に(1)〜(6)のいずれかに記載の1つ以上のピロリシン類似体を非天然アミノ酸として含む抗体。
(10) 各重鎖及び/又は軽鎖に(1)〜(6)のいずれかに記載のピロリシン類似体を非天然アミノ酸として含む、(10)に記載の抗体。
(11) タンパク質、細胞傷害剤、薬物及びポリマーから選択される1つ以上の部分に前記1つ以上の非天然アミノ酸を介してコンジュゲートされる、(7)〜(9)のいずれかに記載の突然変異タンパク質又は抗体。
(12) PEG部分にコンジュゲートされる、(11)に記載の突然変異タンパク質。
(13) 抗体部分にコンジュゲートされる、(11)に記載の突然変異タンパク質。
(14) 細胞傷害剤部分にコンジュゲートされる、(11)に記載の突然変異タンパク質。
(15) 薬物部分にコンジュゲートされる、(11)に記載の突然変異タンパク質。
(16) 1つ以上の非天然アミノ酸を含む突然変異タンパク質の製造における(1)〜(6)のいずれかに記載のピロリシン類似体の使用。
(17) 前記タンパク質が抗体である、(16)に記載の使用。
Claims (15)
- bが1又は2である、請求項1記載の式VIのピロリシン類似体。
- FGが、−N3、−CH=CH2、−C≡CH、−COCH3、−COOCH3、ハロゲンによって置換されたフェニル、又はシクロオクチンを表す、請求項1又は2記載の式VIのピロリシン類似体。
- 請求項1〜4のいずれか1項記載の1つ以上のピロリシン類似体を非天然アミノ酸として含む突然変異タンパク質。
- 請求項1〜4のいずれか1項記載の1つのピロリシン類似体を非天然アミノ酸として含む、請求項5記載の突然変異タンパク質。
- 各重鎖及び/又は軽鎖に請求項1〜4のいずれか1項記載の1つ以上のピロリシン類似体を非天然アミノ酸として含む抗体。
- 各重鎖及び/又は軽鎖に請求項1〜4のいずれか1項記載のピロリシン類似体を非天然アミノ酸として含む、請求項7記載の抗体。
- タンパク質、細胞傷害剤、薬物及びポリマーから選択される1つ以上の部分に前記1つ以上の非天然アミノ酸を介してコンジュゲートされる、請求項5〜8のいずれか1項記載の突然変異タンパク質又は抗体。
- PEG部分にコンジュゲートされる、請求項9記載の突然変異タンパク質。
- 抗体部分にコンジュゲートされる、請求項9記載の突然変異タンパク質。
- 細胞傷害剤部分にコンジュゲートされる、請求項9記載の突然変異タンパク質。
- 薬物部分にコンジュゲートされる、請求項9記載の突然変異タンパク質。
- 1つ以上の非天然アミノ酸を含む突然変異タンパク質の製造における請求項1〜4のいずれか1項記載のピロリシン類似体の使用。
- 前記タンパク質が抗体である、請求項14記載の使用。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261705116P | 2012-09-24 | 2012-09-24 | |
US61/705,116 | 2012-09-24 | ||
US201361862495P | 2013-08-05 | 2013-08-05 | |
US61/862,495 | 2013-08-05 | ||
PCT/EP2013/069888 WO2014044873A1 (en) | 2012-09-24 | 2013-09-24 | Amino acid derivatives |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015531789A JP2015531789A (ja) | 2015-11-05 |
JP2015531789A5 JP2015531789A5 (ja) | 2018-03-29 |
JP6321658B2 true JP6321658B2 (ja) | 2018-05-09 |
Family
ID=49237211
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015532458A Expired - Fee Related JP6321658B2 (ja) | 2012-09-24 | 2013-09-24 | アミノ酸誘導体 |
JP2015532457A Active JP6532404B2 (ja) | 2012-09-24 | 2013-09-24 | 細胞株 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015532457A Active JP6532404B2 (ja) | 2012-09-24 | 2013-09-24 | 細胞株 |
Country Status (11)
Country | Link |
---|---|
US (4) | US9732367B2 (ja) |
EP (2) | EP2898085B1 (ja) |
JP (2) | JP6321658B2 (ja) |
KR (1) | KR102155389B1 (ja) |
CN (2) | CN105026574B (ja) |
AU (1) | AU2013320184B2 (ja) |
BR (1) | BR112015006368B1 (ja) |
CA (1) | CA2885796C (ja) |
HK (2) | HK1211569A1 (ja) |
SG (2) | SG10201702387YA (ja) |
WO (2) | WO2014044873A1 (ja) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2825370A1 (en) | 2010-12-22 | 2012-06-28 | President And Fellows Of Harvard College | Continuous directed evolution |
IN2014DN09922A (ja) | 2012-05-18 | 2015-08-14 | Medical Res Council | |
AU2013320184B2 (en) | 2012-09-24 | 2017-10-12 | Medimmune Limited | Cell lines |
BR112015022641B1 (pt) | 2013-03-15 | 2023-02-28 | Medimmune Limited | Construção de dna e processo de preparação de uma proteína-alvo |
US9764039B2 (en) * | 2013-07-10 | 2017-09-19 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
CN105980350B (zh) | 2013-08-05 | 2018-11-27 | 米迪缪尼有限公司 | 氨基酸衍生物 |
CA2931547A1 (en) | 2013-12-09 | 2015-06-18 | Durect Corporation | Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same |
GB2528227A (en) * | 2014-03-14 | 2016-01-20 | Medical Res Council | Cyclopropene amino acids and methods |
WO2016077052A2 (en) | 2014-10-22 | 2016-05-19 | President And Fellows Of Harvard College | Evolution of proteases |
CN106146663B (zh) * | 2015-04-10 | 2019-11-08 | 北京大学 | 非天然氨基酸标记的新型抗体-药物偶联物及其制备 |
WO2016168631A1 (en) | 2015-04-17 | 2016-10-20 | President And Fellows Of Harvard College | Vector-based mutagenesis system |
US10392674B2 (en) | 2015-07-22 | 2019-08-27 | President And Fellows Of Harvard College | Evolution of site-specific recombinases |
US11524983B2 (en) | 2015-07-23 | 2022-12-13 | President And Fellows Of Harvard College | Evolution of Bt toxins |
WO2017019895A1 (en) | 2015-07-30 | 2017-02-02 | President And Fellows Of Harvard College | Evolution of talens |
US10906990B2 (en) * | 2015-08-19 | 2021-02-02 | Riken | Antibody with non-natural amino acid introduced therein |
CN106929482A (zh) * | 2015-12-31 | 2017-07-07 | 北京大学 | 定点突变的流感病毒、其活疫苗及其制备方法和应用 |
KR20180104106A (ko) | 2016-01-27 | 2018-09-19 | 서트로 바이오파마, 인크. | anti-CD74 항체 접합체, anti-CD74 항체 접합체를 포함하는 조성물 및 anti-CD74 항체 접합체의 이용 방법 |
CN112725282A (zh) * | 2016-01-27 | 2021-04-30 | 北京大学 | 携带正交tRNA/氨酰tRNA合成酶的稳定细胞系的构建 |
CN105524167A (zh) * | 2016-01-30 | 2016-04-27 | 深圳市贝沃德克生物技术研究院有限公司 | 抗乙肝e抗原的绿色荧光抗体的制备方法 |
CN105647918A (zh) * | 2016-02-20 | 2016-06-08 | 深圳市圣必智科技开发有限公司 | 抗乙肝e抗原的红色荧光抗体的制备方法 |
MA45408A (fr) | 2016-06-17 | 2019-04-24 | Magenta Therapeutics Inc | Compositions et procédés pour la déplétion des cellules cd117+ |
WO2018045376A2 (en) * | 2016-09-02 | 2018-03-08 | Ikaria Inc. | Functionally modified polypeptides and radiobiosynthesis |
WO2018044143A1 (ko) * | 2016-09-05 | 2018-03-08 | 한국과학기술원 | 목적 단백질의 위치 특이적 변형이 시공간적으로 조절되는 마우스, 이의 제조방법 및 그 용도 |
KR102013742B1 (ko) * | 2016-09-05 | 2019-11-04 | 한국과학기술원 | 목적 단백질의 위치 특이적 변형이 시공간적으로 조절되는 마우스, 이의 제조방법 및 그 용도 |
JP2020502238A (ja) * | 2016-12-23 | 2020-01-23 | バイスクルアールディー・リミテッド | 新規連結構造を有するペプチド誘導体 |
KR20190107097A (ko) | 2017-01-20 | 2019-09-18 | 마젠타 테라퓨틱스 인코포레이티드 | Cd137+ 세포의 고갈을 위한 조성물 및 방법 |
WO2019010164A1 (en) * | 2017-07-06 | 2019-01-10 | President And Fellows Of Harvard College | EVOLUTION OF ARNT SYNTHÉTASES |
WO2019056002A1 (en) | 2017-09-18 | 2019-03-21 | President And Fellows Of Harvard College | CONTINUOUS EVOLUTION FOR STABILIZED PROTEINS |
US20210060169A1 (en) | 2017-12-27 | 2021-03-04 | Kyowa Kirin Co., Ltd. | Il-2 variant |
US11913044B2 (en) | 2018-06-14 | 2024-02-27 | President And Fellows Of Harvard College | Evolution of cytidine deaminases |
CN110835633B (zh) * | 2018-08-13 | 2021-10-01 | 北京大学 | 利用优化的基因密码子扩展系统制备ptc稳定细胞系及应用 |
US20210356377A1 (en) * | 2018-09-07 | 2021-11-18 | Medimmune, Llc | Methods Of Cell Selection |
CN109553643B (zh) * | 2018-11-29 | 2020-09-22 | 深圳先进技术研究院 | 单糖类似物及包含其的分子探针和该分子探针的应用 |
CN111850020B (zh) * | 2019-04-25 | 2021-05-07 | 苏州鲲鹏生物技术有限公司 | 利用质粒系统在蛋白中引入非天然氨基酸 |
CN111909256A (zh) | 2019-05-10 | 2020-11-10 | 宁波鲲鹏生物科技有限公司 | 多肽衍生物及其制备方法 |
WO2022226189A1 (en) * | 2021-04-21 | 2022-10-27 | Asimov Inc. | Stable production systems for adeno-associated virus production |
EP4330214A2 (en) * | 2021-04-28 | 2024-03-06 | The Regents of the University of California | Bioreactive proteins containing unnatural amino acids |
CA3222899A1 (en) * | 2021-07-29 | 2023-02-02 | Jinwei Yang | Unnatural amino acid, and use thereof, recombinant protein containing same, and recombinant protein conjugate |
EP4130254A1 (en) * | 2021-08-03 | 2023-02-08 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Eukaryotic cell lysates comprising exogenous enzymes and methods for preparing the same |
CN113698468B (zh) * | 2021-09-01 | 2022-10-11 | 浙江新码生物医药有限公司 | 人白细胞介素2-聚乙二醇偶联物及其应用 |
CN113788890B (zh) * | 2021-09-01 | 2022-11-08 | 浙江新码生物医药有限公司 | 一种人白细胞介素2-聚乙二醇偶联物及其应用 |
WO2023164676A1 (en) * | 2022-02-27 | 2023-08-31 | The Regents Of The University Of California | Methods to generate novel acyl-trna species |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3711458A (en) | 1969-08-21 | 1973-01-16 | Research Corp | Substituted and unsubstituted vinyloxycarbonyl groups as amino protecting groups in the syntheses of peptides |
US4512979A (en) | 1981-03-23 | 1985-04-23 | Merck & Co., Inc. | Dipeptides containing thialysine and related amino acids as antihypertensives |
JPH0710451B2 (ja) | 1986-11-25 | 1995-02-08 | 三五重機株式会社 | 鋼板カツタ− |
HU207287B (en) | 1989-01-17 | 1993-03-29 | Biosignal Kutato Fejlesztoe Kf | Polyene fatty acid derivatives of tyrozine-quinaze inhibiting activity and pharmaceutical composition containing them as active component |
US5180674A (en) | 1990-04-16 | 1993-01-19 | The Trustees Of The University Of Pennsylvania | Saccharide compositions, methods and apparatus for their synthesis |
WO2002085923A2 (en) | 2001-04-19 | 2002-10-31 | The Scripps Research Institute | In vivo incorporation of unnatural amino acids |
PT2279753E (pt) | 2001-10-10 | 2016-01-15 | Novo Nordisk As | Remodelação e glicoconjugação de péptidos |
JP4752001B2 (ja) | 2002-10-16 | 2011-08-17 | ザ スクリプス リサーチ インスティチュート | 糖蛋白質合成 |
US20040146941A1 (en) * | 2002-11-04 | 2004-07-29 | Biliang Zhang | Chemical encoding technology for combinatorial synthesis |
MXPA05011127A (es) * | 2003-04-17 | 2006-03-10 | Scripps Research Inst | Expansion del codigo genetico eucariontico. |
DK1812031T3 (en) | 2004-11-01 | 2015-09-14 | Univ California | Compositions and methods for the modification of biomolecules |
JP2007037445A (ja) * | 2005-08-02 | 2007-02-15 | Institute Of Physical & Chemical Research | tRNA合成方法、核酸、アミノアシルtRNA合成方法及び非天然型アミノ酸組み込み蛋白質の製造方法 |
WO2007099854A1 (ja) | 2006-02-22 | 2007-09-07 | Riken | サプレッサーtRNAの合成方法、DNA構築物及びそれを用いた非天然型アミノ酸組み込みタンパク質の製造 |
CA2653748A1 (en) | 2006-05-02 | 2007-11-15 | Allozyne, Inc. | Non-natural amino acid substituted polypeptides |
US20080166766A1 (en) * | 2006-10-18 | 2008-07-10 | The Scripps Research Institute | Genetic incorporation of unnatural amino acids into proteins in mammalian cells |
CA2706889C (en) | 2007-09-20 | 2018-08-28 | Riken | Mutant pyrrolysyl-trna synthetase, and method for production of protein having non-natural amino acid integrated therein by using the same |
JP2011528416A (ja) | 2008-07-18 | 2011-11-17 | アラントゥーム | 自動車の排気ガス浄化用フィルタ装置 |
US20100184134A1 (en) | 2009-01-12 | 2010-07-22 | Sutro Biopharma, Inc. | Dual charging system for selectively introducing non-native amino acids into proteins using an in vitro synthesis method |
US20100203587A1 (en) | 2009-01-13 | 2010-08-12 | Sutro Biopharma, Inc. | Use of dna gyrase inhibitors for in vitro polypeptide synthesis reactions |
WO2010114615A2 (en) | 2009-04-03 | 2010-10-07 | The Scripps Research Institute | A facile system for encoding unnatural amino acids in mammalian cells |
GB2470770A (en) | 2009-06-04 | 2010-12-08 | Medical Res Council | Incorporation of unnatural amino acids having an orthogonal functional group into polypeptides using orthogonal tRNA/tRNA synthetase pairs |
US8921571B2 (en) | 2009-10-06 | 2014-12-30 | The Ohio State University | Pyrrolysine analogs |
CN102666578A (zh) * | 2009-12-21 | 2012-09-12 | Ambrx公司 | 经过修饰的猪促生长素多肽和其用途 |
NZ600361A (en) * | 2009-12-21 | 2014-06-27 | Ambrx Inc | Modified bovine somatotropin polypeptides and their uses |
CN103153927B (zh) | 2010-04-27 | 2017-02-15 | 西纳福克斯股份有限公司 | 稠合的环辛炔化合物及其在无金属点击反应中的应用 |
EP2640745B1 (en) | 2010-09-10 | 2018-11-07 | MedImmune Limited | Bivalent and bispecific anti-il6/anti-il23 antibodies |
DE102010041261A1 (de) | 2010-09-23 | 2012-03-29 | Robert Bosch Gmbh | Flip-Chip Anordnung mit einem Kühlelement und Verfahren zur Herstellung einer Flip-Chip Anordnung |
WO2012038706A1 (en) * | 2010-09-24 | 2012-03-29 | Medical Research Council | Methods for incorporating unnatural amino acids in eukaryotic cells |
US9085514B2 (en) * | 2011-02-03 | 2015-07-21 | Embl | Unnatural amino acids comprising a cyclooctynyl or trans-cyclooctenyl analog group and uses thereof |
KR102182800B1 (ko) | 2012-08-31 | 2020-11-25 | 서트로 바이오파마, 인크. | 아지도 기를 포함하는 변형된 아미노산 |
AU2013320184B2 (en) | 2012-09-24 | 2017-10-12 | Medimmune Limited | Cell lines |
BR112015022641B1 (pt) | 2013-03-15 | 2023-02-28 | Medimmune Limited | Construção de dna e processo de preparação de uma proteína-alvo |
-
2013
- 2013-09-24 AU AU2013320184A patent/AU2013320184B2/en active Active
- 2013-09-24 US US14/430,542 patent/US9732367B2/en active Active
- 2013-09-24 KR KR1020157010354A patent/KR102155389B1/ko active IP Right Grant
- 2013-09-24 US US14/430,412 patent/US9670521B2/en active Active
- 2013-09-24 EP EP13766525.3A patent/EP2898085B1/en active Active
- 2013-09-24 JP JP2015532458A patent/JP6321658B2/ja not_active Expired - Fee Related
- 2013-09-24 BR BR112015006368-3A patent/BR112015006368B1/pt active IP Right Grant
- 2013-09-24 SG SG10201702387YA patent/SG10201702387YA/en unknown
- 2013-09-24 WO PCT/EP2013/069888 patent/WO2014044873A1/en active Application Filing
- 2013-09-24 WO PCT/EP2013/069887 patent/WO2014044872A1/en active Application Filing
- 2013-09-24 CN CN201380060916.XA patent/CN105026574B/zh active Active
- 2013-09-24 CN CN201380060971.9A patent/CN104812734B/zh not_active Expired - Fee Related
- 2013-09-24 SG SG11201502216UA patent/SG11201502216UA/en unknown
- 2013-09-24 JP JP2015532457A patent/JP6532404B2/ja active Active
- 2013-09-24 EP EP13766526.1A patent/EP2897935B1/en not_active Not-in-force
- 2013-09-24 CA CA2885796A patent/CA2885796C/en active Active
-
2015
- 2015-12-18 HK HK15112515.4A patent/HK1211569A1/xx unknown
- 2015-12-18 HK HK15112514.5A patent/HK1211623A1/xx unknown
-
2017
- 2017-06-01 US US15/610,931 patent/US10214761B2/en not_active Expired - Fee Related
- 2017-06-01 US US15/611,116 patent/US10253345B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6321658B2 (ja) | アミノ酸誘導体 | |
CA2918064C (en) | Amino acid derivatives | |
WO2019240288A1 (ja) | 抗体に対する親和性物質、および生体直交性官能基を有する化合物またはその塩 | |
US11946041B2 (en) | Modification of polypeptides | |
AU2014229994B2 (en) | Modification of polypeptides | |
CN108602878B (zh) | C端赖氨酸缀合免疫球蛋白 | |
JP2020514403A (ja) | Mt1−mmpに結合するためのペプチドリガンド | |
JP2017523143A (ja) | オーリスタチン誘導体およびその抱合体 | |
JP6949832B2 (ja) | タンパク質コンジュゲート | |
JP2021528430A (ja) | Psmaに結合するためのペプチドリガンド | |
JP2012520863A (ja) | 多官能化ビオチン類似体を用いた生体分子標識 | |
CN115093376A (zh) | 一种双/多重功能的非天然氨基酸及其偶联物和应用 | |
CN117730076A (zh) | 含有四嗪部分的氨基酸 | |
Xiao | Modulation of protein properties and functions by site-specific protein modification |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160921 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160921 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170720 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170725 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171114 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20180214 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180306 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180405 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6321658 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |